NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marks Major Accomplishments in 2021, Eyes ‘Truly Transformative’ 2022

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, accomplished a host of major milestones in 2021, proving it is on the right path to success. The company was awarded a notice of allowance by the U.S. Patent and Trademark Office for its CYB004 (deuterated psychedelic tryptamine) for the treatment of anxiety disorders and FDA approvals for its co-funded investigator-initiated phase 2 clinical trial. Cybin also confirmed a scientific advice meeting with the UK’s Medical and Healthcare Products Regulatory Agency regarding its lead candidate CYB003 for the treatment of major depressive disorder and alcohol use disorder and also announced positive CYB003 data. Other 2021 highlights included a grant for a psychedelic treatment clinic, securing a Schedule I manufacturing license from the U.S. DEA for its Boston-area research lab, receiving approval from the FDA for its IND application, and the completion of 74 in-vitro and in-vivo evaluations if its expanding portfolio of psychedelic compounds. The company also expanded its operations into Europe and was the first psychedelic company to list on the NYSE American market. Cybin CEO Doug Drysdale is quoted in a recent article as saying, “We believe 2022 will be a truly transformative year for Cybin.” To view the full article, visit https://nnw.fm/et0NP About Cybin Inc. Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only) For more information please visit https://www.networknewswire.com Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer NetworkNewsWire (NNW) New York, New York www.networknewswire.com 212.418.1217 Office [email protected] NetworkNewsWire is part of the InvestorBrandNetwork